Aesculus hippocastanum extract and the main bioactive constituent β-escin as antivirals agents against coronaviruses, including SARS-CoV-2.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 Mar 2024
17 Mar 2024
Historique:
received:
22
11
2023
accepted:
11
03
2024
medline:
18
3
2024
pubmed:
18
3
2024
entrez:
18
3
2024
Statut:
epublish
Résumé
Respiratory viruses can cause life-threatening illnesses. The focus of treatment is on supportive therapies and direct antivirals. However, antivirals may cause resistance by exerting selective pressure. Modulating the host response has emerged as a viable therapeutic approach for treating respiratory infections. Additionally, considering the probable future respiratory virus outbreaks emphasizes the need for broad-spectrum therapies to be prepared for the next pandemics. One of the principal bioactive constituents found in the seed extract of Aesculus hippocastanum L. (AH) is β-escin. The clinical therapeutic role of β-escin and AH has been associated with their anti-inflammatory effects. Regarding their mechanism of action, we and others have shown that β-escin and AH affect NF-κB signaling. Furthermore, we have reported the virucidal and broad-spectrum antiviral properties of β-escin and AH against enveloped viruses such as RSV, in vitro and in vivo. In this study, we demonstrate that β-escin and AH have antiviral and virucidal activities against SARS-CoV-2 and CCoV, revealing broad-spectrum antiviral activity against coronaviruses. Likewise, they exhibited NF-κB and cytokine modulating activities in epithelial and macrophage cell lines infected with coronaviruses in vitro. Hence, β-escin and AH are promising broad-spectrum antiviral, immunomodulatory, and virucidal drugs against coronaviruses and respiratory viruses, including SARS-CoV-2.
Identifiants
pubmed: 38494515
doi: 10.1038/s41598-024-56759-y
pii: 10.1038/s41598-024-56759-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6418Subventions
Organisme : Consejo Nacional de Investigaciones Científicas y Técnicas
ID : 11220200102513CO
Organisme : Agencia Nacional de Promoción Científica y Tecnológica
ID : PICT N° 2018-01588
Informations de copyright
© 2024. The Author(s).
Références
Latreille, E. & Lee, W. L. Modulation of the host response as a therapeutic strategy in severe lung infections. Viruses. 15(7), 1462 (2023).
doi: 10.3390/v15071462
pubmed: 37515150
pmcid: 10386155
Smyk, J. M., Szydłowska, N., Szulc, W. & Majewska, A. Evolution of influenza viruses—drug resistance, treatment options, and prospects. Int. J. Mol. Sci. 23, 12244 (2022).
doi: 10.3390/ijms232012244
pubmed: 36293099
pmcid: 9602850
Group, T.R.C. Dexamethasone in hospitalized patients with COVID-19—preliminary REPORT. N. Engl. J. Med. 384, 693–704 (2020).
Sirtori, C. R. Aescin: Pharmacology, pharmacokinetics and therapeutic profile. Pharmacol. Res. 44, 183–193 (2001).
doi: 10.1006/phrs.2001.0847
pubmed: 11529685
Pittler, M. H. & Ernst, E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst. Rev. 11, CD003230 (2012).
pubmed: 23152216
Domanski, D. et al. Molecular mechanism for cellular response to β-escin and its therapeutic implications. PLoS ONE. 11(10), e0164365 (2016).
doi: 10.1371/journal.pone.0164365
pubmed: 27727329
pmcid: 5058498
Michelini, F. M., Alché, L. E. & Bueno, C. A. Virucidal, antiviral and immunomodulatory activities of β-escin and Aesculus hippocastanum extract. J. Pharm. Pharmacol. 70, 1561–1571 (2018).
doi: 10.1111/jphp.13002
pubmed: 30168142
Salinas, F. M. et al. Aesculus hippocastanum L. seed extract shows virucidal and antiviral activities against respiratory syncytial virus (RSV) and reduces lung inflammation in vivo. Antiviral Res. 164, 1–11 (2019).
doi: 10.1016/j.antiviral.2019.01.018
pubmed: 30711418
Zheng-Zong, L., Hsin-Hsuen, S. & Yen-Mei, L. Inhibitory effect of β-escin on Zika virus infection through the interruption of viral binding, replication, and stability. Sci. Rep. 13(1), 10014 (2023).
doi: 10.1038/s41598-023-36871-1
Vicente, J. et al. The flavonoid cyanidin shows immunomodulatory and broad-spectrum antiviral properties, including SARS-CoV-2. Viruses. 15(4), 989 (2023).
doi: 10.3390/v15040989
pubmed: 37112969
pmcid: 10143848
Nilsson-Payant, B. E. et al. The NF-κB transcriptional footprint is essential for SARS-CoV-2 replication. J. Virol. 95(23), e0125721 (2021).
doi: 10.1128/JVI.01257-21
pubmed: 34523966
Milani, D. et al. p53/NF-kB balance in SARS-CoV-2 infection: from OMICs, genomics and pharmacogenomics insights to tailored therapeutic perspectives (COVIDomics). Front. Pharmacol. 13, 871583 (2022).
doi: 10.3389/fphar.2022.871583
pubmed: 35721196
pmcid: 9201997
Poppe, M. et al. The NF-κB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells. PLoS Pathog. 13(3), e1006286 (2017).
doi: 10.1371/journal.ppat.1006286
pubmed: 28355270
pmcid: 5386326
Huang, H. C. et al. Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. J. Med. Virol. 95(2), e28478 (2023).
doi: 10.1002/jmv.28478
pubmed: 36609964
pmcid: 10107526
Lacasse, É. et al. SARS-CoV-2 Nsp2 contributes to inflammation by activating NF-κB. Viruses. 15(2), 334 (2023).
doi: 10.3390/v15020334
pubmed: 36851549
pmcid: 9964531
Gudowska-Sawczuk, M. & Mroczko, B. The role of nuclear factor kappa B (NF-κB) in development and treatment of COVID-19: Review. Int. J. Mol. Sci. 23(9), 5283 (2022).
doi: 10.3390/ijms23095283
pubmed: 35563673
pmcid: 9101079
Li, T. W. et al. SARS-CoV-2 Nsp14 protein associates with IMPDH2 and activates NF-κB signaling. Front. Immunol. 13, 1007089 (2022).
doi: 10.3389/fimmu.2022.1007089
pubmed: 36177032
pmcid: 9513374
Salinas, F. M. et al. Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs. Antiviral Res. 179, 104817 (2020).
doi: 10.1016/j.antiviral.2020.104817
pubmed: 32387475
pmcid: 7202858
Edwards, A. M., Baric, R. S., Saphire, E. O. & Ulmer, J. B. Stopping pandemics before they start: Lessons learned from SARS-CoV-2. Science. 375, 1133–1139 (2022).
doi: 10.1126/science.abn1900
pubmed: 35271333
Okomo, U., Idoko, O. & Kampmann, B. The burden of viral respiratory infections in young children in low-resource settings. Lancet Glob. Health. 8(4), e454–e455 (2020).
doi: 10.1016/S2214-109X(20)30037-1
pubmed: 32087816
Watson, A. & Wilkinson, T. Respiratory viral infections in the elderly. Ther. Adv. Respir. Dis. 15, 1753466621995050 (2021).
doi: 10.1177/1753466621995050
pubmed: 33749408
pmcid: 7989115
Cohen, M. S. Early treatment to prevent progression of SARS-CoV-2 infection. Lancet Respir. Med. 10, 930–931 (2022).
doi: 10.1016/S2213-2600(22)00213-2
pubmed: 35688163
pmcid: 9173720
D’Abramo, A., Vita, S. & Nicastri, E. The unmet need for COVID-19 treatment in immunocompromised patients. BMC Infect. Dis. 22, 930 (2022).
doi: 10.1186/s12879-022-07918-x
pubmed: 36503419
Therapeutics and COVID-19: Living Guideline (v13.1). World Health Organization (WHO). https://app.magicapp.org/#/guideline/6914 .
Maffei, M. E., Salata, C. & Gribaudo, G. Tackling the future pandemics: Broad-spectrum antiviral agents (BSAAs) based on A-type proanthocyanidins. Molecules. 27, 8353 (2022).
doi: 10.3390/molecules27238353
pubmed: 36500445
pmcid: 9736452
Dhama, K. et al. Medicinal and therapeutic potential of herbs and plant metabolites/extracts countering viral pathogens—current knowledge and future prospects. Curr. Drug Metab. 19(3), 236–263 (2018).
doi: 10.2174/1389200219666180129145252
pubmed: 29380697
Wu, C. Y. et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. USA. 101(27), 10012–10017 (2004).
doi: 10.1073/pnas.0403596101
pubmed: 15226499
pmcid: 454157
Khan, S. et al. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway. Elife. 10, e68563 (2021).
doi: 10.7554/eLife.68563
pubmed: 34866574
pmcid: 8709575
Zheng, M. et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 22(7), 829–838 (2021).
doi: 10.1038/s41590-021-00937-x
pubmed: 33963333
pmcid: 8882317
Planès, R., Bert, J. B., Tairi, S., BenMohamed, L. & Bahraoui, E. SARS-CoV-2 envelope (E) protein binds and activates TLR2 pathway: A novel molecular target for COVID-19 interventions. Viruses. 14(5), 999 (2022).
doi: 10.3390/v14050999
pubmed: 35632741
pmcid: 9146335
Goldenthal, K. L, Midthun, K. & Zoon, K.C. Control of viral infections and diseases. Medical Microbiology. 4th ed. Chapter 51 (1996).
Ijaz, M. K. et al. Microbicidal actives with virucidal efficacy against SARS-CoV-2 and other beta- and alpha-coronaviruses and implications for future emerging coronaviruses and other enveloped viruses. Sci. Rep. 11, 562 (2021).
doi: 10.1038/s41598-021-84842-1